A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)

Eligibility: Inclusion Criteria
  •   Confirmed diagnosis of symptomatic multiple myeloma (MM).
  •   Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2.
  •   Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, or Velcade® (bortezomib), cyclophosphamide, dexamethasone (VCd), and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted.
  •   Participants within 12 months from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria.
Exclusion Criteria
  •   Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapy.
  •   Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma.
  •   Known central nervous system/meningeal involvement of MM.
  •   Prior history of malignancies, other than MM, unless the participant has been free of the disease for >= 5 years.
  •   Other protocol-defined Inclusion/Exclusion criteria apply.